ArticleInvestigational new drugs2026
Prostate cancer cells' growth is decreased by novel MYC inhibitors.
Article in Investigational new drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The MAX (MYC-associated protein X) was discovered as an obligate heterodimer of MYC, a protein product of a prolific proto-oncogene that is dysregulated in over three-fourths of cancers. Targeting MYC directly is fraught with challenges due to the disordered structure of the MYC protein that is not conducive for small molecule inhibitor design. Therefore, the MYC/MAX protein-protein interaction provides an opportunity for indirect targeting of MYC. We compared the efficacy of first- and second-generation MYC/MAX small molecular inhibitors, 10,058-F4 and 3jc48-3 respectively, and tested the novel class of proteomimetic MYC/MAX inhibitor JKY-2-169 on inhibiting growth of human prostate cancer cell line DU145 in 2D culture. In addition, we validated the efficacy of inhibitors using 3-dimensional (3D) systems: 3D microcapsules and human prostate cancer spheroids generated by harvesting fresh cancerous tissue from human radical prostatectomy surgical specimens. Treatment in both 3D models showed that 3jc48-3 and JKY-2-169 reduced cell viability. Analysis of patient-derived spheroids before and after treatment showed that spheroid growth increased significantly over time only in the DMSO control group, while inhibitor-treated spheroids did not show significant growth during the same period; among the treatment groups, only 3jc48-3 significantly reduced spheroid size compared with the DMSO control. The results suggest that the proteomimetic and second-generation MYC inhibitors suppress cell growth at lower concentrations compared to the first-generation inhibitors. Comparative proteomic analysis of treated and untreated DU145 cells, based on a pre-defined twofold expression threshold, identified common cellular pathways altered by MYC/MAX inhibition primarily involving cytoskeletal organizations, cell cycle regulation, metabolism, and RNA-related functions. This study provides promising preliminary in vitro support for further investigation and development of novel MYC inhibitors.
Indexed as
Identifiers
42047739What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.